BACKGROUND: Diabetes mellitus and hypertension are closely linked, but the long-term blood pressure effects of glucose-lowering therapy and hyperglycemia are not clear. METHODS: We examined the effects of intensive insulin therapy and hyperglycemia on the development of hypertension in the Diabetes Control and Complications Trial (DCCT) and its observational follow-up, the Epidemiology of Diabetes Intervention and Complications (EDIC) study. Incident hypertension was defined as 2 consecutive study visits with a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or use of antihypertensive medications to treat high blood pressure. RESULTS:Participants were enrolled from August 23, 1983, through June 30, 1989. During a 15.8-year median follow-up, 630 of 1441 participants developed hypertension. During the DCCT, the incidence of hypertension was similar comparing participants assigned to intensive vs conventional therapy. However, intensive therapy during the DCCT reduced the risk of incident hypertension by 24% during EDIC study follow-up (hazard ratio, 0.76; 95% confidence interval [CI], 0.64-0.92). A higher hemoglobin A(1c) level, measured at baseline or throughout follow-up, was associated with increased risk for incident hypertension (adjusted hazard ratios, 1.11 [95% CI, 1.06-1.17] and 1.25 [95% CI, 1.14-1.37], respectively, for each 1% higher hemoglobin A(1c) level), and glycemic control appeared to mediate the antihypertensive benefit of intensive therapy. Older age, male sex, family history of hypertension, greater baseline body mass index, weight gain, and greater albumin excretion rate were independently associated with increased risk of hypertension. CONCLUSIONS: Hyperglycemia is a risk factor for incident hypertension in type 1 diabetes, and intensive insulin therapy reduces the long-term risk of developing hypertension.
RCT Entities:
BACKGROUND:Diabetes mellitus and hypertension are closely linked, but the long-term blood pressure effects of glucose-lowering therapy and hyperglycemia are not clear. METHODS: We examined the effects of intensive insulin therapy and hyperglycemia on the development of hypertension in the Diabetes Control and Complications Trial (DCCT) and its observational follow-up, the Epidemiology of Diabetes Intervention and Complications (EDIC) study. Incident hypertension was defined as 2 consecutive study visits with a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or use of antihypertensive medications to treat high blood pressure. RESULTS:Participants were enrolled from August 23, 1983, through June 30, 1989. During a 15.8-year median follow-up, 630 of 1441 participants developed hypertension. During the DCCT, the incidence of hypertension was similar comparing participants assigned to intensive vs conventional therapy. However, intensive therapy during the DCCT reduced the risk of incident hypertension by 24% during EDIC study follow-up (hazard ratio, 0.76; 95% confidence interval [CI], 0.64-0.92). A higher hemoglobin A(1c) level, measured at baseline or throughout follow-up, was associated with increased risk for incident hypertension (adjusted hazard ratios, 1.11 [95% CI, 1.06-1.17] and 1.25 [95% CI, 1.14-1.37], respectively, for each 1% higher hemoglobin A(1c) level), and glycemic control appeared to mediate the antihypertensive benefit of intensive therapy. Older age, male sex, family history of hypertension, greater baseline body mass index, weight gain, and greater albumin excretion rate were independently associated with increased risk of hypertension. CONCLUSIONS:Hyperglycemia is a risk factor for incident hypertension in type 1 diabetes, and intensive insulin therapy reduces the long-term risk of developing hypertension.
Authors: Jørgen V Bjørnholt; Gunnar Erikssen; Sverre E Kjeldsen; Johan Bodegård; Erik Thaulow; Jan Erikssen Journal: J Hypertens Date: 2003-07 Impact factor: 4.844
Authors: Aruna V Sarma; James M Hotaling; Ian H de Boer; Rodney L Dunn; Mary K Oerline; Karandeep Singh; Jack Goldberg; Alan Jacobson; Barbara Braffett; William H Herman; Rodica Pop-Busui; Hunter Wessells Journal: J Hypertens Date: 2019-05 Impact factor: 4.844
Authors: Melody R Palmer; Sarah K Holt; Aruna V Sarma; Rodney L Dunn; James M Hotaling; Patricia A Cleary; Barbara H Braffett; Catherine Martin; William H Herman; Alan M Jacobson; Hunter Wessells Journal: J Sex Med Date: 2017-08-26 Impact factor: 3.802
Authors: Ian H de Boer; Xiaoyu Gao; Patricia A Cleary; Ionut Bebu; John M Lachin; Mark E Molitch; Trevor Orchard; Andrew D Paterson; Bruce A Perkins; Michael W Steffes; Bernard Zinman Journal: Clin J Am Soc Nephrol Date: 2016-10-24 Impact factor: 8.237
Authors: Ian H de Boer; Maryam Afkarian; Tessa C Rue; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Wanjie Sun; Bernard Zinman Journal: J Am Soc Nephrol Date: 2014-06-12 Impact factor: 10.121
Authors: Meena Garg; Manikkavasagar Thamotharan; Gerald Pan; Paul W N Lee; Sherin U Devaskar Journal: Am J Physiol Endocrinol Metab Date: 2009-12-15 Impact factor: 4.310
Authors: S Abdo; C-S Lo; I Chenier; A Shamsuyarova; J G Filep; J R Ingelfinger; S-L Zhang; J S D Chan Journal: Diabetologia Date: 2013-04-23 Impact factor: 10.122